Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Palvella Therapeutics Stock Up 0.4 %
Shares of PVLA stock opened at $12.05 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday. They issued an “overweight” rating on the stock.
Read More
- Five stocks we like better than Palvella Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- How to Most Effectively Use the MarketBeat Earnings Screener
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Retail Stocks Investing, Explained
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
